3SBio (1530) AI Stock Analysis

• Market Cap: $58.17B
• Dividend Yield: 1.03%
• Average Volume (3M): 51.28M
• Price to Earnings (P/E): 25.9
• Beta (1Y): 0.94
• Revenue Growth: 14.36%
• EPS Growth: 33.22%
• Country: HK
• Employees: 5,577
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 0.45
• Shares Outstanding: 2,398,580,800
• 10 Day Avg. Volume: 37,041,779
• 30 Day Avg. Volume: 51,275,387
• PEG Ratio: 1.00
• Price to Book (P/B): 3.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 57.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $23.55
• Price Target Upside: -6.36% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 69 Neutral
• Price Target: HK$28.00 ▲(11.33%Upside)

3SBio's stock shows strong financial stability and upward technical momentum, but is countered by overvaluation concerns and inconsistency in cash flow management. The lack of earnings call data and corporate events limits further insights.

Positive Factors

International Collaboration

707 (PD-1/VEGF) demonstrates global BIC potential, with early data suggesting significant opportunities for international collaboration.

Pipeline Expansion

3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.

Revenue Growth

3SBio delivered a strong performance, with revenue increasing 16.5% YoY to RMB9.1bn, driven by the robust growth of TPIAO, Mandi, and other products.

Negative Factors

Market Competition

The need for continuous in-licensing to strengthen its portfolio mix indicates competition in the pharmaceutical market.

3SBio Business Overview & Revenue Model

Company Description

3SBio Inc. is a leading biopharmaceutical company in China, specializing in the research, development, manufacturing, and marketing of biopharmaceutical products. The company primarily focuses on therapeutic areas such as oncology, nephrology, and auto-immune diseases. Its core products include recombinant human erythropoietin (rhEPO) and other innovative biologics, which are significant in treating anemia in cancer patients undergoing chemotherapy and patients with chronic kidney disease.

How the Company Makes Money

3SBio generates revenue through the sale of its biopharmaceutical products, particularly its flagship product, recombinant human erythropoietin (rhEPO), which is extensively used in the treatment of anemia associated with chronic kidney disease and chemotherapy. The company also invests in research and development to expand its product portfolio and pipeline in high-demand therapeutic areas. Collaborations and partnerships with other pharmaceutical companies and research institutions augment its revenue streams by enabling the development and commercialization of new biopharmaceutical products. Additionally, 3SBio leverages its manufacturing capabilities to produce biosimilars and novel biologics, further contributing to its earnings.

3SBio Financial Statement Overview

Summary

3SBio demonstrates robust financial health with strong revenue and profit growth, solid balance sheet stability, and effective cash management. However, cash flow consistency needs improvement due to fluctuating capital expenditures and investing cash flows.

Income Statement

3SBio shows a strong income statement with consistent revenue growth from 2019 to 2024. The gross profit margin is robust, indicating efficient cost management, and the net profit margin has improved significantly over the years, demonstrating enhanced profitability. The EBIT and EBITDA margins are healthy, showcasing strong operational performance.

Balance Sheet

The balance sheet reflects a solid equity base with a decreasing debt-to-equity ratio over the years, signaling improved financial stability. Return on Equity (ROE) is strong, indicating effective utilization of equity. The equity ratio indicates a sound proportion of assets funded by equity, although the increase in total liabilities in recent years suggests a need for cautious financial management.

Cash Flow

Cash flow from operations has been positive, reflecting good cash management and business operations. However, the free cash flow growth is inconsistent due to fluctuating capital expenditures and investing cash flows, which may pose a risk to liquidity. The operating cash flow to net income ratio indicates healthy cash conversion, but the absence of 2024 cash flow data limits full analysis.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.11B	7.82B	6.86B	6.38B	5.59B
Gross Profit	7.83B	6.64B	5.67B	5.28B	4.52B
EBITDA	2.93B	2.53B	2.75B	2.26B	1.59B
Net Income	2.09B	1.55B	1.92B	1.65B	835.79M
Balance Sheet
Total Assets	24.21B	23.63B	21.99B	19.21B	17.68B
Cash, Cash Equivalents and Short-Term Investments	5.79B	5.99B	7.01B	4.70B	4.36B
Total Debt	3.55B	4.84B	4.47B	2.63B	2.91B
Total Liabilities	6.18B	7.11B	6.59B	4.55B	4.58B
Stockholders Equity	15.44B	14.03B	12.96B	12.23B	10.69B
Cash Flow
Free Cash Flow	2.24B	1.38B	1.21B	432.57M	363.09M
Operating Cash Flow	3.20B	2.08B	2.18B	1.58B	1.34B
Investing Cash Flow	-1.36B	-1.35B	-3.72B	-1.29B	-1.87B
Financing Cash Flow	-2.25B	-352.98M	714.91M	-481.12M	1.55B

3SBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Positive. The current price of 25.15 is above the 20-day moving average (MA) of 22.36, above the 50-day MA of 18.05, and above the 200-day MA of 9.84, indicating a bullish trend. The MACD of 1.55 indicates Negative momentum. The RSI at 70.70 is Negative, neither overbought nor oversold. The STOCH value of 83.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1530.

3SBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2269	74 Outperform	$104.36B	28.93	8.17%	―	7.52%	-1.92%
2696	70 Outperform	HK$28.42B	34.18	31.65%	―	4.23%	47.71%
1177	69 Neutral	$95.33B	50.24	6.14%	1.50%	7.63%	-24.23%
1530	69 Neutral	$58.17B	25.93	14.19%	1.03%	14.36%	33.22%
1801	61 Neutral	$130.97B	―	-0.72%	―	49.33%	90.96%
1877	59 Neutral	HK$35.28B	―	-19.78%	―	25.96%	39.58%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%

3SBio Corporate Events

3SBio Inc. Announces AGM Results, Dividend Payment, and Committee Changes

3SBio Inc. announced the results of its Annual General Meeting (AGM) held on June 25, 2025, where all proposed resolutions were passed by poll. The company also declared a final dividend payment and announced changes to its Nomination Committee. These developments are likely to impact the company’s governance structure and shareholder returns, potentially strengthening its position in the biotechnology sector.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Announces Board Roles and Functions

3SBio Inc., a company incorporated in the Cayman Islands, has announced the roles and functions of its board of directors and board committees. The announcement details the positions of executive, non-executive, and independent non-executive directors within the audit, nomination, and remuneration committees. This update is crucial for stakeholders to understand the governance structure and leadership dynamics within 3SBio, potentially impacting the company’s strategic direction and decision-making processes.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Updates Nomination Committee Terms of Reference

3SBio Inc. has outlined the terms of reference for its Nomination Committee, which is responsible for identifying and recommending suitable candidates for the company’s board of directors. The committee, comprising a majority of independent non-executive directors, plays a crucial role in overseeing board performance evaluations and developing nomination guidelines, thereby impacting the company’s governance and strategic direction.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Announces Annual General Meeting with Key Resolutions

3SBio Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shenyang, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, declaration of a final dividend, and re-appointment of auditors. The meeting will also address resolutions related to the issuance of additional shares, which could impact the company’s capital structure and shareholder value.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Partners with Pfizer for Global Licensing of Oncology Antibody

3SBio, Inc. has entered into an exclusive licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707, granting Pfizer rights to develop, manufacture, and commercialize the product worldwide, excluding mainland China. This agreement includes an upfront payment of $1.25 billion to 3SBio, with potential additional payments up to $4.8 billion, and positions 3SBio strategically in the global oncology market, enhancing its industry standing and providing significant financial benefits.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio’s 707 Injection Receives Breakthrough Therapy Designation in China

3SBio Inc. announced that its anti-VEGF/PD-1 bispecific antibody, known as 707 Injection, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer. This designation will accelerate the drug’s development and potential market launch, reflecting 3SBio’s strengthened position in the oncology sector and its commitment to advancing cancer treatment options.